Webbplatsen kommer inte fungerar helt korrekt om er webbläsares JavaScript funktion är inaktiverad.
}
Out-of-the-box gene editing analysis

Countagen

Countagen offers simple-to-use consumable reagent kits that allow users to analyze gene editing efficiency and specificity with the same high precision as high-end instrumentation, but in a much more affordable way. It reliably counts and identifies gene edits with high accuracy using only basic laboratory equipment.

Countagen

CEO:

Felix Neumann

First investment year:

2022

Business sector:

Life Science, Medtech

Investment manager: Stina Wallmark Visit website